REGENXBIO INC. DL-,0001 WKN: A140E0 ISIN: US75901B1070 Kürzel: RB0 Forum: Aktien Thema: Hauptdiskussion

REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy https://www.prnewswire.com/news-releases/regenxbio-announces-orphan-drug-designation-granted-to-rgx-202-a-novel-gene-therapy-candidate-for-the-treatment-of-duchenne-muscular-dystrophy-301429654.html

REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021 https://www.prnewswire.com/news-releases/regenxbio-presents-additional-positive-interim-data-from-trials-of-rgx-314-in-wet-amd-and-diabetic-retinopathy-using-suprachoroidal-delivery-at-aao-2021-301423126.html

RegenxBio’s deal with AbbVie just closed. It could mean more than $1B for the local company. https://www.bizjournals.com/washington/news/2021/11/12/regenxbio-abbvie-close-deal-eye-disease-treatment.html RegenxBio Inc. has closed a massive development and commercialization deal with Chicago’s AbbVie Inc., two months after announcing the agreement that stands to shovel move than $1 billion to the Rockville biotech. The partners said Tuesday they have closed that transaction, to bring to market the local gene therapy company’s treatment candidate for multiple eye diseases, now in clinical trials for wet age-related macular degeneration (AMD), diabetic retinopathy and other chronic retinal illnesses. Now, AbbVie (NYSE: ABBV) pays RegenxBio (NASDAQ: RGNX) $370 million upfront. But the deal also carries the potential for an additional $1.38 billion in development, regulatory and commercial milestones. ...

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=847521

REGENXBIO Reports Third Quarter 2021 Financial Results and Operational https://www.prnewswire.com/news-releases/regenxbio-reports-third-quarter-2021-financial-results-and-operational-highlights-301414492.html

Regenxbio-Solid Biosciences' PDC releases white paper for AAV gene therapy development https://seekingalpha.com/news/3762777-regenxbio-solid-biosciences-pdc-releases-white-paper-for-aav-gene-therapy-development ... The draft white paper proposes a framework that can be applied to AAV gene therapies to facilitate the use of the accelerated approval pathway at the U.S. FDA. ...

REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting https://finance.yahoo.com/news/regenxbio-presents-positive-initial-data-152300587.html

https://seekingalpha.com/news/3748236-regenxbio-posts-biggest-intraday-loss-in-over-a-year-after-data-from-wet-amd-trial

https://www.biospace.com/article/releases/regenxbio-presents-positive-initial-data-from-phase-ii-aaviate-trial-of-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery-and-provides-trial-update-at-retina-society-54th-annual-scientific-meeting/

https://finance.yahoo.com/news/regenxbio-announces-rgx-314-data-110500392.html

Chardan Capital Stick to Their Buy Rating for RegenXBio https://www.investing.com/news/chardan-capital-stick-to-their-buy-rating-for-regenxbio-2614547

AbbVie and REGENXBIO Announce Eye Care Collaboration https://www.prnewswire.com/news-releases/abbvie-and-regenxbio-announce-eye-care-collaboration-301374836.html - AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise - Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases - REGENXBIO to receive $370 million upfront payment ...

REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2021-financial-results-and-operational-highlights-301351442.html

REGENXBIO and Abeona update on arbitration of licensing dispute https://seekingalpha.com/news/3716050-regenxbio-and-abeona-update-on-arbitration-of-licensing-dispute

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting https://www.prnewswire.com/news-releases/regenxbio-presents-additional-positive-interim-data-from-phase-iii-trial-of-rgx-121-for-the-treatment-of-mps-ii-hunter-syndrome-at-american-society-of-gene-and-cell-therapys-24th-annual-meeting-301291376.html • RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events • Biomarkers and measures of neurodevelopmental function from patients in Cohorts 1 and 2 continue to indicate CNS activity following RGX-121 administration • Evidence of systemic enzyme expression and biomarker activity continues to be observed • REGENXBIO recently initiated dosing of patients in Cohort 3 ...

https://www.prnewswire.com/news-releases/regenxbio-reports-first-quarter-2021-financial-results-and-operational-highlights-301284916.html